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Abstract
 
To detect caspase activities in intact apoptotic cells at the single cell level, cell-permeable fluo-
rogenic caspase substrates were synthesized incorporating the optimal peptide recognition mo-
tifs for caspases 1, 3/7, 6, 8, and 9. Caspase activities were then assessed at various times after in
vitro treatment of mouse thymocytes with dexamethasone or anti-Fas antibody. Dexametha-
sone induced the following order of appearance of caspase activities as judged by flow cytome-
try: LEHDase, WEHDase, VEIDase, IETDase, and DEVDase. Since the relative order of
caspases 3 (DEVDase) and 6 (VEIDase) in the cascade has been controversial, this caspase acti-
vation order was reexamined using confocal microscopy. The VEIDase activity appeared before
DEVDase in every apoptotic cell treated with dexamethasone. In contrast, anti-Fas stimulation
altered this sequence: IETDase was the first measurable caspase activity and DEVDase preceded
VEIDase. In an attempt to determine the intracellular target of the potent antiapoptotic agent
 
carbobenzoxy-valyl-alanyl-aspartyl(
 
b
 
-methyl ester)-fluoromethyl ketone (Z-VAD[OMe]-
FMK), we examined its ability to inhibit previously activated intracellular caspases. However,
no significant reductions of these activities were observed. These fluorogenic caspase substrates
allow direct observation of the caspase cascade in intact apoptotic cells, showing that the order
of downstream caspase activation is dependent on the apoptotic stimulus.
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Introduction
 
Since the seminal finding that the 
 
Caenorhabditis elegans
 
death gene 
 
ced-3 
 
encodes a protein homologous to the
 
mammalian protease IL-1
 
b
 
–converting enzyme (ICE)
 
1
 
 (1),
a family of related proteases has been described. Termed
caspases, this family is characterized by both a catalytic cys-
teinyl residue and a strong preference for an aspartyl residue
in the P
 
1
 
 position of their substrate recognition sequence.
Both structural and functional studies have shown that
caspases also recognize the P
 
4
 
 amino acid, and recent stud-
ies using combinatorial chemistry have suggested a division
of the caspase family into three subfamilies based on pep-
tide substrate recognition (2). The ICE subfamily (caspases
1, 4, and 5) prefers a bulky hydrophobic amino acid such as
tyrosine or tryptophan at P
 
4
 
, the caspase 3 subfamily
(caspases 2, 3, and 7) prefers a second aspartic acid residue
at this site, and the caspase 6 subfamily (caspases 6, 8, and 9)
prefers a branched hydrophobic side chain such as valine.
Caspases are expressed in cells as inactive proenzymes,
which must be proteolytically processed in order to acquire
activity. Consistent with the finding that the prototypic
cleavage sites for such processing have the distinctive aspar-
tic acid at P
 
1
 
, various caspases have been found to activate
other procaspases, and a cascade of activating caspases has
been described in cells undergoing apoptosis. Evidence has
accumulated that the caspase cascade is normally initiated
by oligomerization of either procaspase 8 or procaspase 9
via Fas-associated death domain protein (FADD) or apop-
totic protein activating factor 1 (apaf-1), respectively. The
subsequent order of the caspase activation cascade has been
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 apaf-1, apoptotic protein activating fac-
tor 1; DTT, dithiothreitol; FADD, Fas-associated death domain protein;
 
ICE, IL-1
 
b
 
–converting enzyme; PI, propidium iodide. 
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analyzed by ordering caspase processing events in cytoplas-
mic extracts of apoptotic cells, in conjunction with specific
inhibitors. However, recent studies of caspase 9 indicate
that procaspase processing is necessary but not sufficient for
enzymatic activity (3), and other studies attempting to or-
der the caspase cascade have resulted in conflicting propos-
als regarding the relative sequence of activation of caspases
3 and 6. Two studies have suggested that caspase 6 acti-
vates procaspase 3 (4, 5), while two studies have suggested
the reverse order (6, 7). One major problem with analyzing
the caspase cascade in extracts is that events controlled by the
subcellular localization of regulatory components may not
be accurately reproduced. The autoactivation of long pro-
domain caspases occurs in large complexes that are still not
well understood; critical components such as cytochrome
c, apoptosis inducing factor (AIF), and procaspases 2, 3, and
9 are found in the mitochondrial intramembrane space (8–
11); transcriptional events clearly lie upstream of caspase ac-
tivation in many examples of apoptosis; and Bcl-2 family
members move from a cytosolic to membrane localization
during apoptosis (12).
The above complexities point out the need for a means
to monitor caspase activation in intact apoptotic cells, so
that the concepts derived from study of recombinant com-
ponents and extracts of apoptotic cells can be tested in a
physiological setting. To this end, we have designed and
synthesized cell-permeable fluorogenic caspase substrates
with specificity for caspases 1, 3/7, 6, 8, and 9 (13). These
substrates are peptides of 18 amino acids, with caspase rec-
ognition motifs in the center, and rhodamine derivatives
covalently attached near their termini. As previously shown
noncovalent cyclization can occur in such modified pep-
tides via intramolecular complexation of rhodamines with
consequent quenching of the rhodamine fluorescence until
proteolysis breaks the peptide linkage (13, 14). The two as-
sociated rhodamine dye molecules of the intact substrate
appear to form a hydrophobic surface mediating the mem-
brane permeability of these substrates (14–16). We have
used these intracellular caspase substrates in conjunction
with flow cytometry and confocal microscopy to examine
caspase activities in the classic apoptotic system of thy-
mocytes treated with corticosteroid or anti-Fas antibody in
vitro. In the former case, the caspase cascade is triggered by
apaf-1–mediated aggregation of procaspase 9 (17, 18) while
in the latter case it is via FADD-mediated procaspase 8 ag-
gregation, largely independent of procaspase 9 and the Bid
amplification loop (19, 20).
We have also addressed the question of the pharmaco-
logical target of the widely used potent apoptosis blocker
carbobenzoxy-valyl-alanyl-aspartyl(
 
b
 
-methyl ester)-fluoro-
methyl ketone (ZVAD[OMe]-FMK). This compound has
been found to block a wide variety of apoptosis systems in
vitro and has also been reported to protect mice from the
lethal effects of intravenously injected anti-Fas, as well as
ischemia-reperfusion in a stroke model (21, 22). Since
ZVAD(OMe)-FMK is widely regarded as a nonselective
inhibitor of caspases, we expected that it would inhibit the
intracellular caspase activities detected by our substrates.
 
However, we found that although ZVAD(OMe)-FMK
blocks intracellular caspase activation in thymocytes when
added before or at the same time as dexamethasone, it does
not significantly inhibit any detectable intracellular caspase
activities after they have already become activated.
 
Materials and Methods
 
Materials.
 
Thymocytes were prepared from 4–6-wk-old
C57BL/6 mice obtained from Frederick Cancer Center. RPMI
1640 and FCS were from HyClone. Dexamethasone, DMSO,
Hepes, CHAPS, Triton X-100, leupeptin, E64, and iodoaceta-
mide were from Sigma-Aldrich, and dithiothreitol (DTT) was
from Pierce Chemical Co. Hamster anti–murine Fas antibody
(Jo-2) was obtained from BD PharMingen, and PE-labeled goat
F(ab
 
9
 
)
 
2
 
 anti–hamster IgG was from Caltag. The apoptosis inhibi-
tor Z-VAD(OMe)-FMK was purchased from Alexis Biochemi-
cals (some confusion exists about this compound, as not all sup-
pliers make it clear that the normal commercial product is a
methyl ester). PhiPhiLux™ and CaspaLux™ cell-permeable fluo-
rogenic substrates were from OncoImmunin, Inc. Recombinant
caspases 3, 6, 7, and 8 were obtained from BD PharMingen and
Medical Biological Laboratories (Nagoya, Japan). Solvents such as
HPLC grade dichloromethane, methanol, and acetonitrile were
from Fisher Scientific. Propidium iodide (PI) and the fluoro-
phores 5
 
9
 
,6
 
9
 
-carboxytetramethylrhodamine succinimidyl ester
and 5
 
9
 
,6
 
9
 
-rhodamine green carboxylic acid succinimidyl ester
were from Molecular Probes. Reverse phase HPLC equipment
and columns were from Waters Corp. and SynChrom, Inc.
 
Caspase Substrates.
 
The reagents and methods used for pep-
tide synthesis and derivatization have been described in detail pre-
viously (14). In brief, peptides were synthesized using both an
automated peptide synthesizer and by manual solid phase meth-
odology, and subsequently purified by reverse phase HPLC. Pep-
tides were subjected to mass spectrometric analysis (PeptidoGenic
Research) to determine the molecular mass and confirm peptide
structure and composition. Each purified peptide was derivatized
with the appropriate fluorophore as described previously (14).
Substrates were purified into single components of homodoubly
derivatized peptides by reverse phase HPLC and further charac-
terized by absorption and fluorescence spectroscopy.
 
Caspase Activity Measurements in Extracts and Intact Thymo-
cytes.
 
Single cell suspensions of thymocytes were cultured in
RPMI 1640 with 10% FCS at a concentration of 10
 
6
 
 cells/ml.
Dexamethasone (final concentration, 0.1 
 
m
 
M) and Z-VAD
(OMe)-FMK (final concentration, 50 
 
m
 
M) were added at the in-
dicated times from stock solutions in DMSO (100 mM for dexa-
methasone and 200 mM for Z-VAD[OMe]-FMK). For anti-Fas
stimulation, wells in a 24-well plate were coated with anti-Fas
antibody (20 
 
m
 
g/ml; 250 
 
m
 
l per well) overnight at 37
 
8
 
C. After
twice washing the wells with medium containing 10% FCS, 4 
 
3
 
10
 
6
 
 thymocytes were added per well. After culture at 37
 
8
 
C in a
5% CO
 
2
 
 atmosphere for the indicated times, cells were centri-
fuged and resuspended in 75 
 
m
 
l of each substrate (10 
 
m
 
M) in 1.5-
ml Eppendorf tubes. The open tubes were placed in the CO
 
2
 
 in-
cubator for an additional 60 min. After washing in saline, cells
were analyzed by flow cytometry. Caspase activity measurements
in extracts with several known inhibitors and noninhibitors were
carried out using fluorometers from Photon Technology Interna-
tional and SLM-AMINCO. Cell lysates were prepared using a
cell lysate buffer consisting of 50 mM Hepes, pH 7.5, 10% (wt/
vol) sucrose, 0.1% (wt/vol) CHAPS, 0.5% (wt/vol) Triton X-100, 
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and 10 mM DTT. The substrate (10 
 
m
 
M) was prepared in 50
mM Hepes, pH 7.5, with 10 mM DTT. All measurements were
made at 37
 
8
 
C using a thermostated cell holder in a 150-
 
m
 
l quartz
cuvette (3 
 
3
 
 3.45 mm; Starna Cells, Inc.). The temperature of
the substrate solution was preequilibrated for 20 min, ensuring
temperature equilibration by having a flat base line before cell ly-
sate addition. A 10-
 
m
 
l aliquot from an apoptotic thymocyte lysate
was added to 110 
 
m
 
l of substrate solution. The fluorescence in-
tensity was then monitored for 30–60 min. The initial velocity
was calculated from the linear portion of the fluorescence in-
crease. Various amounts of inhibitors were added to the cell lysate
for 20 min before addition of the cell lysate mixture to the sub-
strate solution.
 
Flow Cytometry.
 
Instruments from both Becton Dickinson
(FACSort™ and FACScan™) and Beckman Coulter (EPICS XL)
were used in this study. 10
 
5
 
 PI-negative cellular events were ana-
lyzed for each file using FL1 versus FL3 dot plots to establish a
PI-negative gate using a polygon region. Throughout the entire
time course of experiments, the determined PI-positive popula-
tion of any sample was never 
 
.
 
20%. The EPICS XL was used for
the forward scatter histograms and PI-gated fluorescence histo-
grams shown in Fig. 2. In experiments with time course activa-
tion with anti-Fas antibody and with those of dexamethasone and
carbobenzoxy-valyl-alanyl-aspartyl-fluoromethyl ketone (ZVAD-
FMK), the caspase activity of the cell population and the order of
caspase activation were determined by obtaining the mean fluo-
rescence channel of all PI-negative cells using CELLQuest™
(Becton Dickinson) or EXPO™ (Beckman Coulter) software.
 
Confocal Microscopy.
 
Cells were incubated with various sub-
strates at 10 
 
m
 
M while suspended in RPMI 1640 plus 10% FCS,
10 mM Hepes, and 0.1 
 
m
 
M dexamethasone. Cell suspensions
were transferred to a thermostated chamber with a no. 1 coverslip
bottom, allowed to settle, and viewed on a ZEISS LSM410 laser
scanning confocal microscope system using a 63
 
3
 
, 1.4 NA objec-
tive. Substrates were present at 10 
 
m
 
M throughout the course of
the induction and imaging. Samples were excited using a 488/
518-nM krypton/argon laser, and fluorescent and Nomarski im-
ages were acquired every 5 min. Fluorescent images were ac-
quired as single optical sections 2–3 
 
m
 
m in thickness, and bright-
ness/contrast settings were adjusted so that the fluorescent signal
of cells without fluorescent substrate was near background. As the
substrates are cleaved in apoptotic cells, cellular fluorescence shifts
from below to above the fluorescence of the bulk solution in the
same plane. Changes in cell size and fluorescence were analyzed
using Image-Pro
 
®
 
 Plus (Media Cybernetics). The outlines of indi-
vidual cells were manually traced from digitized RGB images,
and cell area and integrated fluorescence intensities were calcu-
lated.
 
Results
 
Peptide Substrate Cleavage by Apoptotic Thymocyte Ex-
tracts.
 
The caspase substrates used in these studies were
based on optimal peptide recognition motifs for various
caspases as reported by peptide library studies (2) and are
described in Table I. To assess whether cleavage of these
substrates in apoptotic thymocytes was due to caspases, we
examined extracts from untreated fresh thymocytes, or
from thymocytes treated with dexamethasone. We found
that the DEVD substrate was cleaved 25-fold faster by apop-
totic thymocyte extracts than by fresh thymocyte extracts
(on a cell basis), as expected from studies with other
DEVD substrates (23). Fig. 1 shows the effect of various
protease inhibitors on the apoptotic DEVDase activity,
giving an inhibition profile expected for a caspase. Thus
DEVD-CHO is a potent blocker, followed by ZVAD-
FMK, which together with the inhibition by iodoaceta-
mide implicates a cysteine protease. The complete inhibi-
tion by DEVD-CHO is consistent with the absence of
proteases other than caspase 3 or a very closely related pro-
tease in the apoptotic thymocyte cell lysate that might
cleave the DEVDase substrate and generate fluorescence
increases. Additionally, the lack of inhibition by E-64 or
leupeptin is not compatible with this activity being due to
lysosomal cathepsins or calpain, leaving caspases as the re-
maining candidate intracellular enzyme class responsible
for the activity in extracts (24).
 
Table I.
 
Amino Acid Sequence of Cell-permeable Fluorogenic 
Caspase Substrates Used in This Study
 
Substrate
Target
caspase Activity Sequence
PhiPhiLux Caspase 3/7 DEVDase
 
KDPC
 
5
 
G
 
DEVD
 
GIDGC
 
5
 
PKGY
 
CaspaLux-3PE Procaspase 3
processing
IETDase
 
KDPC
 
5
 
G
 
IETD
 
SGVGC
 
5
 
PKGY
 
CaspaLux-6 Caspase 6 VEIDase
 
KDPC
 
5
 
GL
 
VEID
 
NGGC
 
5
 
PKGY
 
CaspaLux-9 Caspase 9 LEHDase
 
KDPC
 
5
 
G
 
LEHD
 
GINGC
 
5
 
PKGY
 
CaspaLux-1 Caspase 1 WEHDase
 
KDPC
 
5
 
G
 
WEHD
 
GINGC
 
5
 
PKGY
 
The amino acid residues constituting the major protease recognition motif
(P
 
4
 
 to P
 
1
 
) are shown in boldface. Caspase cleavage occurs at the COOH
end of the P
 
1
 
 amino acid. The IETD recognition sequence is preferred by
caspase 8 also. The fluorophores are covalently conjugated through the
 
e
 
-amino groups of lysine side chains. C
 
5
 
 is 
 
e
 
-aminocaproic acid.
Figure 1. Inhibition of DEVDase activity in apoptotic thymocyte ex-
tract using PhiPhiLux™ substrate. An extract of mouse thymocytes ex-
posed to 0.1 mM dexamethasone for 6 h was incubated in fluorometer
cuvettes at 378C with 10 mM PhiPhiLux™ substrate with or without the
indicated protease inhibitors. Enzymatic activity was calculated from the
rate of increase of fluorescence. 
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To confirm further that these substrates are cleaved by a
caspase when loaded into apoptotic cells, we have carried
out an HPLC analysis of the recovered intact substrate and
the cleaved substrate fragments from the apoptotic thy-
mocytes that have been incubated with these substrates for
15–30 min. When the fluorescent products in extracts of
such apoptotic thymocytes were examined, the initial
cleavage products detected were derived from a cleavage at
the intended P
 
1
 
 aspartic acid in both cases, with subse-
quent secondary breakdown products formed (data not
shown).
 
Intracellular Caspase Activities in Dexamethasone-treated Thy-
mocytes.
 
Quantitation of intracellular caspase activities in
apoptotic thymocytes treated with dexamethasone in vitro
is shown in Fig. 2. For these experiments, the apoptotic
cells were sampled after various times of incubation as indi-
cated, the five rhodamine green–based caspase substrates
 
were loaded into aliquots of the cell suspension, and flow
cytometry was subsequently carried out. By this approach,
the period of substrate exposure was equivalent for all cells
analyzed, allowing a comparison between different stages in
the caspase cascade.
In all cases, the 1-h time point shown in Fig. 2 A gave
identical profiles to fresh thymocytes, and this single peak
was assumed to represent unhydrolyzed substrate taken up
uniformly by the cells. Fresh thymocytes run without expo-
sure to substrate had a single peak with 
 
z
 
10-fold less fluo-
rescence (data not shown). Examination of all apoptotic
profiles from all caspase substrates shows that a second dis-
crete peak with an intensity 
 
z
 
10-fold higher than the initial
fluorescence is formed with further incubation time, and
this peak increasingly dominates the profile. The VEIDase
activity profiles were unique in exhibiting two discrete
peaks of increased fluorescence intensity, and at 6–7 h the
Figure 2. Analysis of caspase activation by flow
cytometry. (A) Dexamethasone (final concentra-
tion 0.1 mM) was added to freshly isolated mouse
thymocytes that were incubated at 378C for vari-
ous times before washing and adding one of five
caspase substrates. Incubation with substrate was
then carried out for an additional 60 min. The time
of exposure of cells to dexamethasone is indicated
in the left margin of each panel. Forward angle
light scatter from incubation without substrate ad-
dition is shown at the left; these histograms were
identical to those of cells with substrates. (B) Thy-
mocytes cultured on anti-Fas–coated wells were
analyzed as in A.1823 Komoriya et al.
population was divided roughly equally among three fluo-
rescence levels.
The sequence of caspase activation can be best seen by
examination of the profiles at the 2-h time point, which
shows highest activity for the LEHD substrate, followed by
WEHDase (or ICE-like activity), VEIDase, and finally
IETDase and DEVDase. Although about half the cells had
increased their fluorescence by z10-fold with the LEHD
substrate at 2 h after addition of dexamethasone, a compa-
rable increase in DEVDase activity was not observed until
5 h. As expected, the onset of the IETDase activity (caspase
3 processing enzyme) preceded the appearance of the
DEVDase activity. Since all five substrates showed unique
patterns of increased fluorescence with time, it appears that
distinct enzymes with different kinetics of activation are re-
sponsible for the proteolytic activities of these substrates in
thymocytes.
Intracellular Caspase Activities in Anti-Fas–treated Thymo-
cytes. To compare the intracellular caspase activities in
thymocytes with a distinctly different upstream activation
pathway, we have carried out experiments parallel to the
above with anti-Fas antibody (Fig. 2 B). Compared with
dexamethasone, caspase activation by saturating amounts of
anti-Fas antibody was slow, and there was more heteroge-
neity of caspase activity in the apoptotic cells. The order of
activation of caspases was determined by plotting the mean
fluorescence of the PI-negative cells between 1 and 3 h for
each of the five substrates (data not shown), which increased
in the order: IETDase, WEHDase, DEVDase, LEHDase,
and VEIDase. Since the IETD substrate was optimal for
caspase 8, this result is consistent with expectations that it
initiates this cascade. Although the progression of caspase
activation was less distinct for anti-Fas triggering than dexa-
methasone triggering, it is very clear that for the anti-Fas
case DEVDase activity precedes VEIDase, in contrast to
dexamethasone treatment of these cells.
Other differences between induction by the two stimuli
were the distribution profiles and extent of induction.
Thus, although stimulation by dexamethasone resulted in a
bimodal pattern for all substrates except VEIDase (which
became trimodal at later times), thymocytes stimulated
with anti-Fas developed trimodal patterns with all sub-
strates. To ascertain if anti-Fas–mediated IETDase activa-
tion of a subpopulation of thymocytes was due to differen-
tial cell surface expression of Fas, flow cytometry using the
triggering anti-Fas antibody was used to compare Fas sur-
face expression on IETDasehigh and IETDaselow subpopula-
tions. These showed identical histograms, indicating that
differences in surface Fas expression did not account for the
subpopulation differences in caspase activation among thy-
mocytes (data not shown).
Ordering of VEIDase versus DEVDase by Confocal Micros-
copy. Because two recent studies with apoptotic Jurkat cell
lysates showed that procaspase 6 was activated by caspase 3
(6, 7), the observation that VEIDase activity increased be-
fore the DEVDase activity in dexamethasone-treated thy-
mocytes (Fig. 2 A) was unexpected. The relative order of
appearance of these two activities was addressed using con-
focal microscopy with cells continuously exposed to a mix-
ture of the VEID and DEVD substrates derivatized with
rhodamine green and tetramethyl rhodamine fluorophores,
respectively, with dexamethasone added along with the
substrates at time zero. Confocal images of these thy-
mocytes at 20-min intervals are shown in Fig. 3 A. The
initial color appearing in individual cells from 90 to 190
min is invariably the green VEIDase activity. With increas-
ing time, this VEIDase activity is replaced by the yellow
color, signifying the presence of both VEIDase and DEVD-
ase activities. Cells appearing red, indicative of DEVDase
activity without accompanying VEIDase activity, are not
obvious in any images. Thus, this independent approach
using confocal microscopy confirms the VEIDase before
DEVDase order found by flow cytometry for this apoptotic
system. Fig. 3 B also shows the separate images used to
construct the frames of Fig. 3 A, illustrating the distribution
of fluorescent enzymatic products within these apoptotic
thymocytes. It can be seen that the cells in the lower left
panel with green VEIDase activity that have not yet be-
come positive for red DEVDase display a relatively uniform
distribution of fluorescence throughout the cells. However,
those cells that have also become DEVDase positive and
have therefore been VEIDase positive for some time appear
yellow due to the accumulation of the green as well as red
enzymatic products in cytoplasmic organelles. These more
intensely stained cells seem likely to account for the highest
intensity peak of VEIDase activity in Fig. 2 A. Fig. 3 C
shows the result of quantitatively analyzing a representative
individual cell from these confocal images. When exam-
ined on a frame by frame basis, the green and red fluores-
cent signals have distinct patterns of increase that cannot be
accounted for by assuming that the red DEVDase activity is
based on a less sensitive detection of the VEIDase activity.
Further examination of the images in Fig. 3 reveals an
apparent size increase as the cells become caspase positive.
This is best seen by finding a green cell in one frame of
Fig. 3 A and following it backward with time in the frames
shown. In every case, the Nomarski images show that be-
fore becoming caspase positive, the thymocytes show a
smaller diameter than the green (VEIDase only) cells. It
appears in Fig. 3 A that the yellow cells at 190 min may
also be smaller than they were when they were green in
earlier frames. Nomarski images of some of these large cells
are suggestive of blebbing, with smooth round mem-
branes. When projected as a time-lapse sequence of
Nomarski images without fluorescence overlay, the mem-
branes and cytoplasmic organelles appear in vigorous mo-
tion suggestive of zeiosis (25; data not shown). Fig. 3 C
quantitates the size increase of one apoptotic thymocyte in
this experiment, and shows that the onset of this increase
precedes the appearance of caspase cleavage products. The
increase in diameter seen in confocal images appears to be
reflected in the small shift to the right in the forward scat-
ter peak at 2 h as seen in Fig. 2 A. This scatter shift was
transient, as by 3 h or later the light scatter histogram re-
turned nearly to that of the 1-h time point. It is only later,
at 5–7 h, that the histograms show a peak of lower scatter-1824 Caspase Activities in Intact Apoptotic Thymocytes
Figure 3. Confocal microscopy images of dexamethasone-treated thymocytes. (A) Time course of cells incubated with 10 mM DEVDase (red) and
VEIDase (green) substrates. The apoptosis inducing agent, 0.1 mM dexamethasone, and two substrates were present continuously. Confocal images of
cells at 20-min intervals starting at 90 min are shown here. The yellow color indicates the presence of both caspase activities. (B) Fluorescence images of
caspases in apoptotic thymocytes derived from VEIDase (CaspaLux-6™) and DEVDase (PhiPhiLux™) are shown separately to assess their differential ac-
tivity, as well as the additive image similar to A. These images are from the 140-min time point of the experiment shown in A. The Nomarski image is
in the lower right. The dark images of cells in each fluorescence image correspond to those cells in which intracellular caspase activation is not yet detect-
able. (C) Time course of activation of the DEVDase (circles) and VEIDase (squares) activities compared with the cell cross-sectional area (triangles) plot-
ted from the single cell shown. Both area and fluorescence are shown in arbitrary units, relative to the 92-min time point.1825 Komoriya et al.
ing particles building up that could be attributed to classical
apoptotic cell shrinkage.
Pharmacological Target of ZVAD(OMe)-FMK. The abil-
ity to detect intracellular caspase activities allowed us to
study the pharmacological target of the potent apoptosis in-
hibitor ZVAD(OMe)-FMK. We have previously shown
that ZVAD(OMe)-FMK specifically blocks the appearance
of dexamethasone-induced apoptotic nuclear morphology
and thymocyte death in vitro (26). In this experiment, we
sought to identify which intracellular caspases were inacti-
vated by ZVAD(OMe)-FMK treatment of thymocytes. To
this end, we added ZVAD(OMe)-FMK to thymocytes at
various times relative to the addition of dexamethasone and
then examined caspase activity by flow cytometry at 6 h.
Activity was assessed by the mean fluorescence channel
number of PI-negative cells. Fig. 4 shows the results of this
experiment, which confirms that the addition of ZVAD
(OMe)-FMK blocks apoptosis when added before or simul-
taneously with dexamethasone. However, when addition of
this inhibitor was delayed, the intracellular activity of all
caspases detected rose, with no significant selective deple-
tion of activity. When ZVAD(OMe)-FMK was added at
4 h, the observed activity at 6 h of all caspases was 70–80%
of uninhibited levels. As seen in Fig. 4, the time course for
development of ZVAD(OMe)-FMK–resistant caspase ac-
tivity is strikingly parallel for the different substrates, and the
constant difference between the activity ratios of the differ-
ent substrates are accounted for by the method used to de-
fine caspase positivity. When thymocytes were pretreated
with ZVAD(OMe)-FMK followed by washing before dexa-
methasone addition, minimal inhibition was seen (data not
shown). As discussed below, these data provide no evidence
for significant inactivation of any of the detectable intracel-
lular caspases by ZVAD(OMe) treatment of intact cells, but
do suggest that ZVAD(OMe)-FMK blocks an upstream
component in the caspase activation cascade.
Discussion
Intracellular Caspase Substrates. The cell-permeable fluo-
rogenic substrates used this study (Table I) are based on
peptides of 18 amino acids containing central optimal tet-
rapeptide caspase recognition/cleavage sequences, with
two identical fluorophores covalently attached near their
termini. Previous studies have shown that in solution such
substituted peptides assume an oval-shaped structure due to
the formation of intramolecular excitonic H-dimers be-
tween the two fluorophores (27, 28). In such rhoda-
mine-derivatized dimers, the fluorophore fluorescence is
quenched 90–99%. When a protease cleaves the peptide
backbone of this complex, the cyclic structure incorporat-
ing the fluorophores is broken and two highly fluorescent
substituted peptide fragments are generated. A surprising
finding has been that caspase substrates of this design are
permeable to cell membranes, thus allowing reporting of a
variety of intracellular environments. While normally pep-
tides of z18 amino acids are impermeable to cells without
a specialized means of transport, we speculate that the
head-to-head complex of rhodamine fluorophores forms a
hydrophobic surface capable of interacting with lipid bilay-
ers to allow passive diffusion of these substrates across the
bilayer. After intracellular cleavage, the rate of diffusion of
the peptide–fluorophore reaction products across the mem-
brane is significantly reduced since they lack the large hy-
drophobic surface provided by the fluorophore–fluoro-
phore dimer of the substrate. The intracellular fluorescent
signal generated by these substrates is predominantly due to
the accumulation of fluorescent peptide cleavage products.
Until the apoptotic loss of membrane integrity, this fluores-
cent signal reflects a balance between the rate of substrate
hydrolysis and the rate of loss of peptide hydrolysis prod-
ucts from the cell. Although analyzing intracellular caspase
activities using such substrates lacks many of the advantages
of traditional biochemical approaches (e.g., limited num-
bers of purified components in dilute solutions), the ability
to assess enzymatic activity in intact cells avoids some of the
potential artifacts of such approaches and provides an im-
portant opportunity to test molecular models in a physio-
logically meaningful setting (29).
In the above description of our results, we have been
careful to avoid ascribing the enzymatic activities with par-
ticular substrates to individual caspases, even though the
substrates have been designed based on optimal caspase rec-
ognition motifs (Table I). An initial question arises as to
whether the activities seen represent caspases, as cleavage at
any peptide bond between the lysines will give a signal
with these substrates. Candidate cytoplasmic proteases that
could be responsible for cleavage of these substrates include
lysosomal cathepsins, the proteasome, and calpain. Fig. 1
shows that activity on the DEVDase substrate in apoptotic
thymocyte extracts is specifically blocked by inhibitors tar-
geted to caspase 3/7. Moreover, HPLC analysis of fluoro-
Figure 4. Effect of ZVAD(OMe)-FMK treatment on in situ caspase
activation. Thymocytes were treated with 0.1 mM dexamethasone in
vitro and analyzed after a total of 6 h incubation. The apoptosis inhibitor
ZVAD(OMe)-FMK was added at various times of incubation as indi-
cated, and the caspase activities were assessed by flow cytometry. The re-
sults are expressed as ratios of mean fluorescence channel number com-
paring the activity in the presence of 50 mM Z-VAD(OMe)-FMK with
the uninhibited sample for that substrate.1826 Caspase Activities in Intact Apoptotic Thymocytes
phore-bearing peptide substrate fragments from intracellu-
lar digestion in apoptotic thymocytes shows that the initial
primary cleavage is at the expected P1 aspartate (data not
shown). It is clear that all the activities detected are caspase
dependent, since ZVAD(OMe)-FMK blocks their appear-
ance (Fig. 4) as well as other detectable manifestations of
dexamethasone-induced thymocyte apoptosis (26). Thus,
we conclude that activity on these protease substrates in in-
tact apoptotic cells reflects caspases as opposed to other pos-
sible intracellular proteases.
Since the demonstrated peptide cleavage selectivity with
recombinant caspases is not absolute, and the in situ intra-
cellular activities of individual caspases have not been
tested, the attribution of the activities observed to particular
caspases must be made cautiously. We have carried out ex-
periments with several recombinant caspases (3 and 6) to
assess the specificity of some of the substrates used here, in
particular the VEIDase and DEVDase. We have found that
the peptide substrates in Table I demonstrate a far greater
caspase selectivity than the tetrapeptide AMC substrates
(Komoriya, A., B.Z. Packard, and P.A. Henkart, manu-
script in preparation).
Caspase Activities in Intact Cells. Analysis of intracellular
caspase activity in dexamethasone-induced apoptotic thy-
mocytes by flow cytometry (Fig. 2 A) strikingly shows a
“quantal” distribution of caspase activity, with cells having
either a background level of fluorescence due to uncleaved
substrate or a 40-fold higher level of fluorescence, with few
cells at an intermediate level. This quantal higher fluores-
cence level can most simply be explained as that achieved
as a balance between maximal substrate hydrolysis and leak-
age of the fluorescent products out of the cell. The activity
histograms for VEIDase after dexamethasone treatment as
well as all five activities after anti-Fas treatment become tri-
modal, with an additional higher peak. This higher peak
appears to correlate with the accumulation of intense fluo-
rescence within intracellular organelles as seen in the mi-
croscope. The heterogeneity of the intracellular and inter-
cellular caspase activities observed with these intracellular
substrates is a novel observation, not readily detectable with
other methods of measuring caspase activities.
Our results show that after dexamethasone treatment
there is a pattern of progressive caspase activation with
time, as expected for the caspase cascade proposed from
traditional biochemical studies. As shown in Fig. 2 A, this
progression begins with LEHDase, followed by WEHDase,
VEIDase, IETDase, and DEVDase. These activities corre-
spond to the optimal tetrapeptide recognition sequences for
caspases 9, 1, 6, 8, and 3/7, respectively (Table I), and this
order of caspase activation for dexamethasone-treated thy-
mocytes is reasonable when compared with recent studies
with enzyme inhibitors (26) and caspase knockout mice.
This death pathway requires Apaf-1 (17) and caspase 9 (18)
but is independent of caspases 1 and 3 (30, 31) and FADD
(32). Our observation that the first detectable caspase signal
is the LEHDase activity is consistent with caspase 9 activa-
tion as the initiator of the caspase cascade in these cells. Al-
though WEHDase activity seen in Fig. 2 A could be due to
caspase 1, it could also be due to caspases 4 or 5 (2), or po-
tentially to newly described members of the ICE subfamily.
While caspase 1 is presumably not part of the apoptotic
death pathway, it is possible that it is responsible for pro-
cessing cytokines such as IL-1b in the dying cells (33).
The order of caspase activation for anti-Fas–treated thy-
mocytes (Fig. 2 B) is less clear-cut but distinctly different
from dexamethasone-treated thymocytes. The initial activity
increases are in the order IETDase, WEHDase, DEVDase,
LEHDase, and VEIDase. Since IETDase is the preferred
substrate for caspase 8, which is activated by FADD-induced
aggregation of its proenzyme (34), its early activation is
consistent with current ideas about this pathway. The late
activation of LEHDase, the preferred substrate for caspase
9, is consistent with the minor role of the Bid/mitochon-
drial amplification loop in the Fas death pathway in thy-
mocytes (20) and the activation of caspase 9 by downstream
caspases.
Studies in other laboratories on the relative order of acti-
vation of caspases 3 and 6 have yielded conflicting results,
and our data show clearly that even in the same cells differ-
ent triggering signals result in a different relative order of
activation of these downstream caspases. Our observation
that VEIDase activity appears before DEVDase activity in
dexamethasone-treated thymocytes was unexpected given
the studies of Slee et al. (7), which provided clear evidence
that caspase 3 activity is upstream of caspase 6. They used
Western blots to examine caspase activation/processing ini-
tiated by cytochrome c in Jurkat extracts, a model we con-
sidered relevant to thymocytes treated with dexametha-
sone. The most compelling experiments were those in
which removal of individual caspases from the extracts
blocked activation of other caspases, and it was particularly
striking that depletion of caspase 3 abolished the ability of
cytochrome c to trigger the processing of caspase 6, placing
caspase 3 upstream of caspase 6. This same order was de-
duced from studies of the Fas death pathway (6) and are
compatible with our observations of this pathway in thy-
mocytes. On the other hand, an earlier study showed that
addition of purified caspase 6 to a nonapoptotic extract
triggered the processing of caspases 3 and 7, whereas addi-
tion of purified caspase 3 or 7 to a nonapoptotic extract
failed to trigger the processing of caspase 6 (4). These re-
sults suggest that caspase 6 is upstream of caspases 3 and 7.
Recently, Xanthoudakis et al. assayed camptothecin-
treated Jurkat extracts for an enzyme with procaspase 3
processing activity and found that this substrate formed a
complex with Hsp60 which was then processed by caspase
6 (5). These results also favor the activation of caspase 6 be-
fore caspase 3 in the cascade. Our results argue against a
common downstream module of caspase activation, sug-
gesting that different upstream caspases trigger distinct
downstream activation pathways.
The Pharmacological Target of ZVAD(OMe)-FMK. The
finding in Fig. 4 that ZVAD(OMe)-FMK treatment of
apoptotic cells fails to significantly inactivate detectable
caspase activity was unexpected. This compound was syn-
thesized as a stable substitute for the ICE inhibitor ZVAD-1827 Komoriya et al.
FMK, which has a half-life of ,1 h in aqueous solution
(35). It has been widely and successfully used to block apop-
tosis in vitro, and has shown potency in animal models for
diseases involving apoptosis (21, 22). ZVAD(OMe)-FMK
should be membrane permeable since it lacks charges, but
for it to inactivate caspases intracellular esterases are re-
quired to remove the ester, forming the active site reagent
ZVAD-FMK. Since this inhibitor lacks a P4 amino acid
and is a potent upstream blocker of apoptotic pathways
triggered by both death domain receptors and apaf-1 (36),
it is widely assumed that ZVAD-FMK is a general inhibitor
of caspases. A recent solution study showed that ZVAD-
FMK indeed irreversibly inactivates all of the individual
recombinant caspases 1–9, but with a 1,000-fold range in re-
action rates (35). Caspases 1, 5, 8, and 9 show rapid inacti-
vation, with a t1/2 of several seconds at 1 mM ZVAD-FMK,
whereas caspases 2, 4, and 6 react two to three orders of
magnitude more slowly. Since caspases 8 and 9 are the ini-
tial caspases in the two major triggering pathways, these re-
sults appeared to account for the potent antiapoptotic activ-
ity of ZVAD(OMe)-FMK. Thus, we expected to find the
LEHDase and WEHDase activities in apoptotic thymocytes
inactivated by ZVAD(OMe)-FMK treatment. In the ex-
periment shown in Fig. 4, we measured intracellular
caspase activities at 6 h, when all substrates showed substan-
tial activity. ZVAD(OMe)-FMK totally blocked the activa-
tion of all detectable caspases when added before or at the
time of dexamethasone addition, but after these caspases
were activated (e.g., at 4 h), addition of ZVAD(OMe)-
FMK blocked only a minor component of the activities at-
tributable to newly activated enzymes. There was no clear
indication of a selective caspase inactivation predicted by
the differing reaction rates with ZVAD-FMK (35), sug-
gesting that ZVAD(OMe)-FMK acts upstream of the mea-
sured components of the caspase cascade. Extrapolating re-
sults from the biochemical study of ZVAD-FMK reactivity
is difficult, as its cytoplasmic concentration is not known.
There are several possible explanations for our failure to
observe inactivation by ZVAD(OMe)-FMK of previously
activated caspases. Although we believe it unlikely for
the reasons discussed, it is possible we are not measuring
the caspases these substrates were designed for, and that the
LEHDase activity observed is not due to caspase 9. Another
possibility is that the major intracellular caspase activities are
within membrane-bound organelles (as suggested by the
confocal images) and thus not accessible to the active hy-
drophilic ZVAD-FMK inhibitor in the cytoplasm. A third
possibility is that ZVAD(OMe)-FMK or ZVAD-FMK
could be reacting with a critical caspase we have not mea-
sured, or perhaps a cysteine protease that is not a caspase. In
this respect, it is worth noting that the cathepsin B inhibi-
tor carbobenzoxy-phenylalanyl-alanyl-fluoromethyl ketone
(ZFA-FMK) does not block dexamethasone-induced thy-
mocyte apoptosis (26), suggesting a P1 amino acid specific-
ity for the pharmacological target of ZVAD(OMe)-FMK.
It is possible that ZVAD-FMK blocks the putative critical
upstream aggregation-induced autoactivation of procaspase
9. This autoactivation activity, involving processing near
the active site cysteine when the proenzymes are part of a
multimeric complex, is not understood in detail but is pre-
sumably not measurable with the present fluorogenic sub-
strates. ZVAD-FMK may selectively target this activity
(and the homologous autoactivation of procaspase 8) more
efficiently than it inactivates the mature caspases.
Regardless of its precise molecular target, the results in
Fig. 4 clearly indicate that ZVAD(OMe)-FMK acts at an
early stage in the apoptotic pathway, either by inactivating
an upstream caspase or another activity. The inability of
ZVAD(OMe)-FMK to significantly block caspase activa-
tion if added before dexamethasone and then washed out
indicates that this activity is silent before apoptosis is in-
duced. We thus conclude that the pharmacological target
of ZVAD(OMe)-FMK has the following properties: (a) it
is activated early in the apoptosis cascade; (b) it is a com-
mon element in apoptotic pathways induced by many di-
verse triggers; and (c) it has the reactivity of a cysteine pro-
tease with selectivity for a P1 aspartic acid.
We believe that the ability to monitor enzyme activities
in intact functioning cells is an important component of our
efforts to apply the knowledge of enzyme biochemistry to
physiological systems. The caspase substrates described here
provide the first attempt to use this approach for apoptosis,
where there is ample evidence for the importance of cellu-
lar organization in regulating these critical proteolytic medi-
ators. Given the widespread interest in selectively modulat-
ing apoptosis in vivo, we believe that these are useful tools
that can be applied to a variety of other apoptotic systems.
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